Related references
Note: Only part of the references are listed.Discovery of pyrazolopyrimidine derivatives as potent BTK inhibitors with effective anticancer activity in MCL
Fansheng Ran et al.
BIOORGANIC CHEMISTRY (2019)
Targeting BTK in CLL: Beyond Ibrutinib
David A. Bond et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2019)
The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review
Chengyuan Liang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Targeting the B-cell receptor pathway: a review of current and future therapies for non-Hodgkin's lymphoma
Thomas D. Rodgers et al.
EXPERT OPINION ON EMERGING DRUGS (2018)
Targeting Bruton's Tyrosine Kinase Across B-Cell Malignancies
Caspar da Cunha-Bang et al.
DRUGS (2018)
Ability of Bruton's Tyrosine Kinase Inhibitors to Sequester Y551 and Prevent Phosphorylation Determines Potency for Inhibition of Fc Receptor but not B-Cell Receptor Signaling
Andrew T. Bender et al.
MOLECULAR PHARMACOLOGY (2017)
Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations
Adam R. Johnson et al.
ACS CHEMICAL BIOLOGY (2016)
Bruton's Tyrosine Kinase (BTK) Inhibitors in Clinical Trials
Jan A. Burger
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2014)
Targeting Bruton's tyrosine kinase in B cell malignancies
Rudi W. Hendriks et al.
NATURE REVIEWS CANCER (2014)
The kinase Btk negatively regulates the production of reactive oxygen species and stimulation-induced apoptosis in human neutrophils
Fumiko Honda et al.
NATURE IMMUNOLOGY (2012)
Survival of resting mature B lymphocytes depends on BCR signaling via the Igα/β heterodimer
M Kraus et al.
CELL (2004)
Amplification of B cell antigen receptor signaling by a Syk/ITAM positive feedback loop
V Rolli et al.
MOLECULAR CELL (2002)
Signaling network of the Btk family kinases
Y Qiu et al.
ONCOGENE (2000)
Share Paper
